Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Peptide leads new class of chronic pain drugs

For the past 40 years, there has been no major addition to the repertoire of drugs for treating severe, chronic pain. Now, two drugs with a completely different mechanism of action, targeting N-type calcium channels, are making their market debuts in the US and Europe—milestones that have received remarkably little attention. Access options Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF. USD 39.95 Prices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support Author information Authors and Affiliations Ann Arbor, Michigan Ken Garber Authors Ken Garber About this article Cite this article Garber, K. Peptide leads new class of chronic pain drugs. Nat Biotechnol 23, 399 (2005). https://doi.org/10.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

For the past 40 years, there has been no major addition to the repertoire of drugs for treating severe, chronic pain. Now, two drugs with a completely different mechanism of action, targeting N-type calcium channels, are making their market debuts in the US and Europe—milestones that have received remarkably little attention.

Access options

Access through your institution

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Purchase on SpringerLink Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in Learn about institutional subscriptions Read our FAQs Contact customer support

Author information

Authors and Affiliations

Ann Arbor, Michigan

Ken Garber

Authors

Ken Garber

About this article

Cite this article

Garber, K. Peptide leads new class of chronic pain drugs. Nat Biotechnol 23, 399 (2005). https://doi.org/10.1038/nbt0405-399

Download citation

Published: 01 April 2005

Issue date: 01 April 2005

DOI: https://doi.org/10.1038/nbt0405-399

Connected topics

Follow this recovery question